These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16981982)

  • 1. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up.
    Vila-Córcoles A; Ochoa-Gondar O; Ester F; Sarrá N; Ansa X; Saún N;
    BMC Public Health; 2006 Sep; 6():231. PubMed ID: 16981982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
    Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
    Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing pneumococcal vaccination in managed care through telephone outreach.
    Winston CA; Mims AD; Leatherwood KA
    Am J Manag Care; 2007 Oct; 13(10):581-8. PubMed ID: 17927463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
    Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.
    Vila-Corcoles A; Ochoa-Gondar O; Hospital I; de Diego C; Satué E; Bladé J; Ansa X; Guzmán JA; Salsench E; Ramos F
    Hum Vaccin Immunother; 2016 Nov; 12(11):2953-2958. PubMed ID: 27454779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance with influenza and pneumococcal vaccination among patients with chronic obstructive pulmonary disease consulting their medical practitioners in Catalonia, Spain.
    Jiménez-García R; Ariñez-Fernandez MC; Hernández-Barrera V; Garcia-Carballo MM; de Miguel AG; Carrasco-Garrido P
    J Infect; 2007 Jan; 54(1):65-74. PubMed ID: 17049991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era.
    Vila-Corcoles A; Ochoa-Gondar O; Gomez-Bertomeu F; Raga-Luria X;
    Vaccine; 2011 Oct; 29(43):7430-4. PubMed ID: 21803108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥60 years-a population-based retrospective cohort study.
    Kolditz M; Schmitt J; Pletz MW; Tesch F
    Clin Microbiol Infect; 2018 May; 24(5):500-504. PubMed ID: 28830805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Coverage and association with clinical variables of antipneumococcal vaccination of the population over 65 years old in Tarragona-Valls].
    Vila Córcoles A; Ochoa Gondar O; Ansa Echeverría X; Bladé Creixenti J; Palacios Llamazares L; Fuentes Bellido CM
    Rev Esp Salud Publica; 2005; 79(6):645-54. PubMed ID: 16457056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of community dwelling elderly not vaccinated for pneumococcus in 1998 and 2001.
    Hoover DR; Sambamoorthi U; Crystal S
    Prev Med; 2004 Sep; 39(3):517-27. PubMed ID: 15313091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017.
    Vila-Córcoles A; Ochoa-Gondar O; de Diego C; Satué E; Vila-Rovira A; Aragón M
    Euro Surveill; 2019 Jul; 24(29):. PubMed ID: 31339099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
    Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
    Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
    Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
    Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
    Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up.
    Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A; Gomez F; Raga X; de Diego C; Satue E; Salsench E;
    BMC Public Health; 2012 Mar; 12():222. PubMed ID: 22436146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.
    Pírez MC; Algorta G; Cedrés A; Sobrero H; Varela A; Giachetto G; Montano A
    Pediatr Infect Dis J; 2011 Aug; 30(8):669-74. PubMed ID: 21407145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.